Kamada Ltd. (KMDA) Given Consensus Rating of “Strong Buy” by Brokerages
Kamada Ltd. (NASDAQ:KMDA) has received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Analysts have set a 1-year consensus price target of $8.50 for the company and are anticipating that the company will post ($0.04) earnings per share for the current quarter, according to Zacks. Zacks has also given Kamada an industry rank of 111 out of 265 based on the ratings given to related companies.
A number of analysts recently issued reports on KMDA shares. Zacks Investment Research cut Kamada from a “hold” rating to a “sell” rating in a research report on Wednesday, October 5th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Kamada in a research report on Saturday, September 3rd. Jefferies Group reissued a “buy” rating and issued a $7.00 target price on shares of Kamada in a research report on Wednesday, August 31st. Finally, TheStreet raised Kamada from a “sell” rating to a “hold” rating in a research report on Monday, September 26th.
A number of hedge funds have recently bought and sold shares of KMDA. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Kamada during the second quarter worth $1,701,000. Vanguard Group Inc. boosted its stake in Kamada by 19.0% in the second quarter. Vanguard Group Inc. now owns 327,533 shares of the company’s stock worth $1,202,000 after buying an additional 52,195 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Kamada by 2.4% in the first quarter. Renaissance Technologies LLC now owns 170,300 shares of the company’s stock worth $652,000 after buying an additional 4,000 shares during the last quarter. 5.31% of the stock is owned by institutional investors.
Shares of Kamada (NASDAQ:KMDA) opened at 5.67 on Friday. Kamada has a 52-week low of $3.26 and a 52-week high of $5.86. The stock has a 50 day moving average price of $4.93 and a 200-day moving average price of $4.14. The stock’s market capitalization is $206.49 million.
Kamada (NASDAQ:KMDA) last released its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04). The business earned $19.10 million during the quarter, compared to analysts’ expectations of $18.50 million. Kamada had a negative return on equity of 10.59% and a negative net margin of 9.92%. On average, equities research analysts anticipate that Kamada will post ($0.19) EPS for the current fiscal year.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.